This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Receives registration of Valganciclovir powder for oral solution in Germany
Expands patient reach to remotest towns by furthering investment in GoApptiv
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Subscribe To Our Newsletter & Stay Updated
